# Impact of Mirabegron on Erectile Function in BPH Patients

> **NCT04503850** · — · UNKNOWN · sponsor: **Kasr El Aini Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Males With Benign Prostatic Hyperplasia Symptoms

## Interventions

- **DRUG:** Mirabegron 50 MG
- **DRUG:** Alpha Blockers

## Key facts

- **NCT ID:** NCT04503850
- **Lead sponsor:** Kasr El Aini Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-01
- **Primary completion:** 2021-05-01
- **Final completion:** 2021-10-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04503850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04503850, "Impact of Mirabegron on Erectile Function in BPH Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04503850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*